BioPharm International - May 2022

BioPharm International- May 2022

Issue link: https://www.e-digitaleditions.com/i/1467950

Contents of this Issue

Navigation

Page 31 of 35

32 BioPharm International May 2022 eBook www.biopharminternational.com The CDMO Carousel Acquisitions in the CDMO space can give us insight into a company's vision for their future. A ctions speak louder than words, and in the highly competitive biopharmaceutical market large acquisitions are often the equiva lent of shouting one's intentions from the rooftops. In this vein, BioPharm International has collected the latest acquisition news from major contract, development, and manufacturing com- panies (CDMOs) in the hopes of providing insight into possible market movements. THE BIG BIOLOGICS PUSH Merc k KGa A , Da r mstadt, Ger ma ny, a nnou nced its US $78 0 m i l l ion a c q u i sit ion of E xe le a d i n a pr e s s release on Jan. 6, 2022. Exelead, a biopharmaceutical CDMO, specialized in PEGylated products and complex injectable formulations, including the lipid nanoparticle- based drug delivery technology that is key in messenger RNA (mRNA) vaccines and therapeutics (1). That alone would raise an eyebrow, but the statement released with their purchase made their intentions clear: " Novel moda l it ies, pa r t ic u la rly mR NA , present a highly attractive business opportunity as pharma and bio- tech pipelines are increasingly building on them beyond COV I D -19," sa id Belén Ga r ijo, c ha i r of t he e xec- utive boa rd and CEO of Merck KGa A , in the press r e l e a s e . " T h e a c q u i s i t i o n o f E x e l e a d w i l l f u r- ther enable us to capt ure the signif icant potentia l of t he f a s t- g r o w i n g m a rk e t for m R N A t he r apie s b y providing leading CDMO services to our customers." Meanwhi le, Cata lent announced on Apri l 6, 2022 t h a t it h a d a c q u i r e d Va c c i n e M a nu f a c t u r i n g a n d I n no v at ion C e nt r e U K L i m it e d 's biol o g ic s d e v e l- o p m e n t a n d m a n u f a c t u r i n g f a c i l i t y i n O x f o r d , Un it e d K i n g d o m fo r a p p r o x i m a t e l y U S $16 0 m i l- l ion . I n t he a n no u nc e me nt , t he c omp a ny s p e c i f i- ca lly stated that they hoped to have the constr uction GRANT PLAYTER Partnerships for Outsourcing Industry Update nordroden - STOCK.ADOBE.COM

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - May 2022 - BioPharm International- May 2022